The first sample type was human leukemia K562 cells treated with seven anti-cancer medications—etoposide (inhibitor of Topoisomerase II), SN-38 (inhibitor of Topoisomerase I), romidepsin (inhibitor of histone deacetylases), imatinib (inhibitor of BCR-ABL oncogene present in K562), talazoparib (PARP inhibitor), 10074-G5 (c-Myc inhibitor), and YM-155 (DNA intercalator)—and DMSO control for 6, 12, 24, 36, and 48 h in two independent biological replicas. Here, ABL1 is linked to cancer.